To assess the acute effects of nasal continuous positive airway pressure (CPAP) on the 24-hour blood pressure and the secretion of catecholamines in urine and plasma, we investigated the changes in the 24-hour blood pressure and urinary and plasma concentrations of epinephrine (E) and norepinephrine (NE) in 26 men with obstructive sleep apnea (OSA) with and without nasal CPAP. Nasal CPAPresulted in significant decreases in the daytime diastolic pressure (from 86 ± 16 mmHgto 83 ± 12 mmHg), the nighttime diastolic pressure (from 81 ± 12 mmHgto 77 ±9 mmHg) and the nighttime systolic pressures (from 125 ± 15 mmHgto 120 ± 10 mmHg). There was no significant difference between patients with and without CPAPin the daytime or nighttime urinary E level, but patients who received CPAPshowed a significant decrease in daytime urinary NElevel (from 156± 112 |ig/14h to 119 ± 101 |0g/14h) and nighttime urinary NE level (from 143 ±91 |ig/10h to 112 ± 65 |ig/10h). The morning plasma level of NE also decreased (from 371 ± 181 pg/ml to 273 ± 148 pg/ml) in patients who received nasal CPAP (p<0.02), but the plasma level of E remained unchanged. There were no correlations between PSGparameters and the reductions in blood pressure and the catecholamine levels induced by nasal CPAP.These findings suggest that OSA contributes, at least in part, to the development of systemic hypertension by increasing sympathetic nervous activity.
Introduction
Although there is no direct evidence of an association between systemic hypertension and obstructive sleep apnea (OSA) (1) (2) (3) (4) (5) , successful treatment of OSAimproves daytime hypertension, suggesting that there is a causal link between hypertension and OSA (6) (7) (8) (9) . Wepreviously found that the application of short-term nasal continuous positive airway pressure (CPAP) reduces the daytime blood pressure in OSA patients (10) . However, because blood pressure fluctuates during sleep and nasal CPAPis applied only during sleep, it is important to investigate changes in the nighttime blood pressure during nasal CPAP. Wilcox et al (8) and Suzuki et al (9) reported that 5-to 8-week treatment with nasal CPAPsignificantly reduced both the daytime and nighttime blood pressure. However, the acute effect of nasal CPAPon blood pressure has not been examined.
The mechanisms of blood pressure elevation during sleep in OSApatients are not fully understood, but marked oxygen desaturation following an episode of OSAor an increase in sympathetic nervous activity due to microarousal may be involved (1 1-13) . However, the effect of catecholamines on blood pressure in OSApatients is controversial. Somestudies have shown that the urinary level of norepinephrine (NE) during sleep is significantly reduced in OSApatients after tracheostomy or nasal CPAP(14, 15), but Marrone et al (16) reported that the urinary level of epinephrine (E) is decreased and the NE level remains unchanged in patients treated with nasal CPAP. Weinvestigated the acute effects of nasal CPAPon 24-hour blood pressure using a noninvasive blood pressure monitoring system, and also the changes in the daytime and nighttime urinary and plasma levels of NE and E in OSApatients with and without nasal CPAP.
Patients and Methods
We studied 26 men with OSA(47.8 ± ll.1 years) in whom the diagnosis of OSAhad been confirmed by polysomnography (PSG) in an outpatient sleep clinic. This study was permitted by the Institutional HumanInvestigation Committee of Nihon University. All subjects were hospitalized during the present study and received a standard hospital diet (2, 100 Kcal/day, 10 g of sodium/day). Subjects were asked to moderate their consumption of fluids and snacks. Renal function was within normal limits in all subjects (Creatinine: 1.0 ± 0. 1 mg/ml, blood urea nitrogen (BUN): 18 ± 2 mg/ml). Six subjects were being treated with antihypertensive medication (calcium antagonist in 4 patients and angiotensin converting enzyme (ACE) blockers in 2 patients). Antihypertensive medications were withdrawn 3 days before the study. Informed consent was obtained from all subj ects.
Each subject underwent overnight PSGfrom 10 PMto 8 AM using standard techniques as previously described (10) . Analysis and interpretation of the sleep study were performed using standard criteria (17). Blood pressure was monitored at 30-minute intervals during a 24-hour period using an ambulatory blood pressure monitoring system (SpaceLabs 90207, Nihon Koden Co., Tokyo) without nasal CPAP. The 24-h blood pressure was used as the "control day" value. "Daytime" was defined as the period from 8 AMto 10 PMand "nighttime" as the period from 10 PMto 8 AM.Wecalculated the average daytime and nighttime blood pressure.
Daytime and nighttime urine samples were collected for measurement of NEand E by high-performance liquid chromatography (18). Venous blood samples were obtained by a trained nurse at 8 AMafter completion of the PSGrecording before the patient got out of bed and the morning plasma levels of NE and E were measured by high-performance liquid chromatography.
Nasal CPAPtitration was performed to completely abolish snoring and apnea and to maintain a saturation of oxygen (SaO2) >90% during sleep using a commercial CPAPdevice (Tranquility Plus, Healthdyne, GA). The mean CPAP was 10.9 ± 2.7 cmH20. Twenty-four-hour blood pressure monitoring and measurements of urinary and plasma levels of catecholamines were repeated during nasal CPAP,which was administered at night on the day after CPAPtitration (treatment day).
Results are presented as the mean ± SD. Changes of blood pressure during nasal CPAPwere analyzed using a one-way analysis of variance (ANOVA) and a post-hoc test. Group differences before and during treatment were assessed with Wilcoxon's signed rank test for paired data and the MannWhitney U-test for unpaired data. Simple regression analysis was used to determine the relationship between blood pressure and various parameters. The difference was considered statistically significant when the p value was below 0.05.
Results
Severe OSAwas detected in all subjects. The average nighttime blood pressure was significantly lower than the average daytime blood pressure (p<0.01) ( Table 1) . Daytime hypertension (defined as an average systolic pressure >140 mmHg or an average diastolic pressure >90 mmHg) was present in 9 patients, 4 of whomhad been taking antihypertensive medications (calcium antagonist in 3 patients and an ACE blocker in 1 patient). There were no significant differences in blood pressure and catecholamine levels among the 4 subjects whohad been receiving antihypertensive medication and the 22 subjects whohad not been taking these drugs. There were no correlations between daytime and nighttime blood pressure and PSG parameters. The 24-hour blood pressure profile with and without nasal CPAPis shown in Fig. 1 . The systolic pressures at 2 and 4 AMand the diastolic pressures at 4 PM, 4 AM, and 6 AMwere significantly decreased during nasal CPAP (p<0.05). Nasal CPAPsignificantly reduced the average nighttime systolic anddiastolicbloodpressure (from 125 ± 15/81 ± 12to 120± 1 1/ 77 ± 9 mmHg)and the daytime diastolic blood pressure (from
The average daytime and nighttime blood pressures in 9 of the hypertensive subjects were 144 ± 10/97 ± 5 mmHgand 139 ± 12/92 ± 12 mmHg,respectively. There were no differences in age, body mass index (BMI), or PSG parameters between hypertensive and normotensive subj ects. The average nighttime systolic and diastolic pressures decreased significantly (from 139± 12/92± 12mmHgto 132±7/86±9mmHg)duringCPAP in hypertensive subjects (p<0.05).
No correlations were observed between PSGparameters and urinary and plasma catecholamine levels before treatment. There were no significant differences between patients with and without nasal CPAPboth in the daytime and nighttime urinary E levels (Fig. 3) . Nasal CPAP significantly reduced the daytime and nighttime urinary NE levels from 156 ± 112 to 119 + 101 |ig/14h and from 143 ±91 to 1 12± 65 jag/10h, respectively (Fig.  4) . Nasal CPAP did not significantly alter the plasma level ofE, but significantly reduced the NE level (from 385 ± 192 to 270 ± 146 pg/ml; p<0.02) (Fig. 5) . The CPAP-induced changes in blood pressure were not correlated with the urinary and plasma levels of NE (Fig. 6) . In hypertensive subjects, CPAPwas associated with a decrease in the daytime urinary NE level in the rangeof 199± 1 1 |ig/14hto 128 ±75 |Hg/14handwithadecrease in the nighttime NElevel in the range of 105 ± 65 |ig/10h to 89 ± 7 1 |ig/10h, but these changes were not significant. CPAPalso reduced the plasma NElevel in hypertensive subjects, but the change was not significant. The urinary and plasma E levels did not change significantly during nasal CPAPin hypertensive subjects.
Discussion
The relationship between hypertension and OSAremains controversial (1) (2) (3) (4) (5) . In the present study, blood pressures did not correlate with PSGparameters of the severity of OSA, suggesting that OSAis not directly related to hypertension. (/zg/10 h) (pg/ml) A Norepinephrine (urine) A Norepinephrine (plasme) Figure 6 . The relationship between CPAP-induced changes in blood pressures and changes in urinary and plasma levels of norepinephrine at nighttime. ABP: CPAP-inducedchange in blood pressure, ANorpinephrine: CPAP-induced change in urinary and plasma norepinephrine levels.
blood pressure than in daytime blood pressure. Although the daytime systolic blood pressure did not change significantly after short-termnasal CPAP(from 131 + 14 mmHgto 127 ± 15 mmHg), a tendency to decrease was found (p<0.1). If nasal CPAP is applied for a longer duration, the reduction of the nighttime blood pressure may be fixed and the daytime systolic pressure may decrease significantly as well as daytime diastolic pressure. We previously found that 1-to 2-week treatment periods with nasal CPAPwere associated with decreases in the daytime blood pressure in OSApatients (10). Wilcox et al (8) and Suzuki et al (9) also found that a 5-to 8-week treatment period with nasal CPAPwas associated with significant decreases in nighttime blood pressures. However, they studied only a small number of subjects, and it is possible that there were alterations in other factors that can influence blood pressure, such as weight and diet, during the 5-to 8-week treatment period. Therefore, it is possible that the significant reductions in blood pressure reflect the direct effect of nasal CPAPin the present study. The results of the present study suggest that the CPAP-induced decrease in nighttime blood pressures caused the decrease in daytime blood pressure. Thus, OSAmay contribute to the development of daytime hypertension. The mechanisms of hypertension in OSApatients are not fully understood. Somestudies have shownthat sympathetic nervous activity is the major factor in hypertension during sleep (12, 1 3). Waravdekar et al ( 19) have recently demonstrated that muscle sympathetic nerve activity (MSNA), measured by peroneal microneurography, is elevated in OSApatients and that MSNA decreases after nasal CPAPtreatment. However,the role of catecholamines is controversial. Krieger et al (20) observed no changes in urinary levels of E and NEafter nasal CPAPtreatment. Fletcher et al (14) and Baruzzi et al (15) reported that the daytime urinary level of NEwas higher in OSA patients than in control subjects and that the NElevel returned to the control level following tracheostomy or nasal CPAP.In a study by Marrone et al (16) , the urinary E level decreased but the NE level remained unchanged during nasal CPAPin patients with OSA.The present results are consistent with the results of the studies by Fletcheret al (14) and Baruzzi et al (15) :
The daytime and nighttime urinary levels of NEdecreased significantly after nasal CPAP. The plasma level of NEalso decreased after nasal CPAP, although we measured only the early morning plasma level of NE. These findings suggest that nasal CPAPinhibits the secretion of NEduring the daytime and at night in OSApatients. NEinduces generalized vasoconstriction and elevated systolic and diastolic blood pressures. An elevated plasma level of NEis generally believed to reflect sympathetic nervous activity. OSAis associated with repeated episodes ofhypoxemia and sleep arousal, which result in surges of sympathetic nervous activity and transient elevations in blood pressure. Ehlenz et al (21) and Eisenberg et al (22) reported that the plasma level of NEis increased in OSA patients. However, in a study by Jennum et al (23) , the plasma level of E and levels of pancreatic polypeptide decreased in response to nasal CPAPin patients with OSA,while the plasma NElevel remained unchanged. The reason for the discrepancy between their results and the present findings is unclear. The pretreatment of plasma E level in their report was 86 ± 7 pg/ml, which is markedly higher than in other reports (21, 24) and in the present study. It is possible that the methods used to measure plasma levels of E and NE contributed to the difference in findings. Jennum et al used a single isotope derivative technique, whereas we used high-performance liquid chromatography which was used in other recent studies (21, 24) . Weevaluated the changes in catecholamines in both urine and plasma during treatment and observed the same trend in both urine and plasma. Therefore, it is likely that nasal CPAPmainly influenced the NE level but not the E level in patients with OSA. The present findings suggest that nasal CPAPinhibited sympathetic nervous activity during the daytime and at night in OSApatients and that the decrease in NEsecretion may be associated with the reductions in daytime and nighttime blood pressure. Marrone et al ( 1 6) have shown that the daytime and nighttime urinary levels of catecholamines are higher in OSApatients than in normal subjects and that only the urinary level ofE decreases after nasal CPAP.The reason for the discrepancy between their findings and the present results is unclear, but the differences in the subject' s baseline characteristics may be a contributing factor.
Their subjects were all normotensive, while the present study included 9 hypertensive patients and the average blood pressure of our subjects was relatively high. Although we found no direct relationships between the magnitude of the reductions in blood pressure and urinary and plasma levels of NEinduced by nasal CPAP,the present findings suggest that sympathetic nervous activity is, at least in part, an important contributor to hypertension in patients with OSA.
